GL1X · GenesisL1 explorer

MolNFT v1 · #168405 · protein

Crystal structure of human NAA50 in complex with accoa and an inhibitor (compound 4A) identified using DNA encoded library technology

6WFN · N-alpha-acetyltransferase 50: “Crystal structure of human NAA50 in complex with accoa and an inhibitor (compound 4A) identified using DNA…”. X-ray diffraction, 2 ligands (ACO, U2J), 1 pocket (best druggability 0.63). MolNFT v1…

PDB
6WFN
Type
protein
Length
151 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
N-alpha-acetyltransferase 50
EC
2.3.1.258, 2.3.1.-
UniProt
Q9GZZ1
Ligands
ACO, U2J
Pockets
1 · best druggability 0.63

Structure

x-ray diffraction · 1 distinct chain · 32% helix, 36% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AN-alpha-acetyltransferase 50 (EC 2.3.1.258, 2.3.1.-)protein15132% helix, 36% strandQ9GZZ1

Ligands and binding sites

  • ACO · Acetyl coenzyme *A · ligand · chains A
  • U2J · (4S)-1-methyl-N-{(3S,5S)-5-[4-(methylcarbamoyl)-1,3-thiazol-2-yl]-1-[4-(1H-tetrazol-5-yl)benzene-1-carbonyl]pyrrolidin-3-yl}-2,6-dioxohexahydropyrimidine-4-carboxamide · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13330.630.7936ACO, U2J

Compared structures

  • 6WFN · Crystal structure of human Naa50 in complex with AcCoA and an inhibitor (compound 4a)… · the same entry in another collection · chain A against A, TM-score 1.00
  • Q9GZZ1 · AlphaFold monomer V2.0 prediction for N-alpha-acetyltransferase 50 (Q9GZZ1) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.